ZIDOVUDINE

Post-LOE

zidovudine

Hetero

ANDAORALTABLET

Approved

Apr 2008

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ZIDOVUDINE (zidovudine) by Hetero is nucleoside reverse transcriptase inhibitors [moa]. Approved for human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2008.

Drug data last refreshed 14h ago

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT00000754Phase 2Completed

A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3

60 enrolled

HIV Infections

NCT00000830N/ACompleted

Intracellular Pharmacokinetics of Zidovudine Triphosphate in Maternal and Infant Cord Blood Mononuclear Cells.

24 enrolled

HIV InfectionsPregnancy

NCT00002255Phase 1Completed

An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)

HIV Infections

NCT00001025Phase 2Completed

Evaluation of Patients Who Have Not Had Success With Zidovudine

120 enrolled

HIV Infections

NCT00001104Phase 3Completed

A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia

538 enrolled

HIV Infections

Worked on ZIDOVUDINE at Hetero? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.